Prime Medicine, Inc. (PRME) intrinsic value & 10-year financials
Prime Medicine, Inc. (PRME) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue shrank 2.3% a year to $4.6M, with an average return on invested capital of -130.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.47
- Market cap
- $516.2M
- Revenue (FY2025)
- $4.6M
- Revenue growth (7-yr CAGR)
- -2.3%
- ROIC (10-yr avg)
- -130.9%
- Free cash flow (FY2025)
- -$167.1M
PRME 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.6M | -$201.1M | -$1.35 | -$167.1M | -4498.1% | -239.5% |
| FY2024 | $3.0M | -$195.9M | -$1.65 | -$130.2M | -6787.4% | -390.5% |
| FY2023 | $0 | -$198.1M | -$2.18 | -$174.1M | — | -169.3% |
| FY2022 | $0 | -$121.8M | -$4.19 | -$147.9M | — | 119.9% |
| FY2021 | $0 | -$165.4M | -$14.19 | -$38.2M | — | 24.9% |
| FY2020 | $5.2M | -$3.4M | -$0.38 | -$6.2M | -17.9% | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Prime Medicine, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Prime Medicine, Inc. has earned high returns on invested capital, averaging 27.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Prime Medicine, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Prime Medicine, Inc. is modeled at -2.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.50 per share.